Who is sponsoring NCT02905318?

NCT02905318 is sponsored by Canadian Cancer Trials Group.

What condition does NCT02905318 study?

NCT02905318 studies Prostate Cancer.

What is the status of NCT02905318?

NCT02905318 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2026-03-09 · How we verify

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02905318 PHASE2 ACTIVE_NOT_RECRUITING

The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side effects of treatment with palbociclib. The researchers doing this study are also interested in looking for markers that may help predict which patients are most likely to be helped by palbociclib and to see how the cancer cells respond to palbociclib.

Details

Lead sponsor	Canadian Cancer Trials Group
Phase	PHASE2
Status	ACTIVE_NOT_RECRUITING
Enrolment	19
Start date	Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Prostate Cancer

Interventions

Palbociclib

Countries

Canada